Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine

该合同的目标是识别新型佐剂，作为NIAID疫苗佐剂发现计划的一部分，承包商已经开发了一系列新型化合物。作为卫生和公众服务部推进扁虱传播病原体疫苗开发工作的一部分，承包商将对一种针对严重发热和血小板减少综合征病毒(SFTSV)的疫苗的佐剂进行正式比较。目前还没有这种疫苗，承包商有一个模型系统，可以在其中评估这种疫苗的效力。SFTS于2009年首次报告，此后一直在传播。作为一种意外宿主，它在人类中的致死率高达30%，不仅通过扁虱传播，而且还可以在人与人之间传播。在这个项目中，β-丙内酯灭活病毒将与三种实验佐剂(与明胶和Addavax相比)配制，并将评估疫苗的效力。

The objective of the contract is to identify novel adjuvants, as part of the NIAID Vaccine Adjuvant Discovery Program and the contractor has developed a portfolio of novel compounds. As part of HHS’ effort to advance the development of vaccines against tick-borne pathogens, the contractor will conduct a formal comparison of adjuvants for a vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). No such vaccine is currently available, and the contractor has a model system in which the efficacy of such vaccines can be evaluated. SFTS was first reported in 2009 and has since been spreading. It has a fatality rate in humans, an accidental host, of up to 30% and is transmitted not only by ticks, but can also be spread from person to person. In this project, beta-propiolactone-inactivated virus will be formulated with three experimental adjuvants (in comparison to Alum and Addavax) and the efficacy of the vaccines will be evaluated.